Neuromodulation.co

Category: Vagal nerve stimulation

Vagus Nerve Stimulation (VNS) Overview

What Is Vagus Nerve Stimulation? Vagus nerve stimulation (VNS) is a neuromodulation technique that uses gentle electrical pulses to influence the activity of the vagus nerve and its extensive connections throughout the brain and body. Nearly 80–90% of vagal fibers carry sensory information toward the brain. Stimulation can modulate key regions involved in autonomic regulation and emotional processing. It also affects neuroimmune signaling. This makes the vagus nerve a highly effective gateway for therapeutic intervention. This makes the vagus nerve a highly effective gateway for therapeutic intervention. VNS is delivered through either implantable or non-invasive systems. Implantable cervical VNS involves placing a small pulse generator under the skin of the chest, which is connected to a helical electrode wrapped around the left vagus nerve in the neck. This allows tailored and long-term stimulation programs (Beekwilder & Beems, 2010). Regardless of delivery mode, stimulation of vagal afferents activates brainstem hubs such as the nucleus tractus solitarius and locus coeruleus. These centers are crucial in regulating neurotransmitters like norepinephrine and serotonin. These pathways contribute to improved autonomic balance and enhanced cortical plasticity. Additionally, they modulate inflammatory signaling through mechanisms such as the cholinergic anti-inflammatory pathway. Originally developed for drug-resistant epilepsy, VNS has evolved into a broad therapeutic platform. This evolution is supported by growing clinical and mechanistic evidence across neurological, psychiatric, autonomic, inflammatory, and pain-related disorders (Austelle et al., 2024; Goggins et al., 2022). History of Vagus Nerve Stimulation The development of vagus nerve stimulation (VNS) spans more than a century. It began with early attempts to electrically modulate the cervical vagus nerve to suppress seizures in the late 1800s. James Corning’s pioneering experiments utilized mechanical compression and rudimentary electrical stimulation of the carotid sheath. These efforts foreshadowed the concept of neuromodulation despite limited scientific understanding at that time (Austelle et al., 2024). Modern clinical VNS emerged in the 1980s. Zabara and colleagues developed implantable stimulators and showed seizure-interrupting effects in canine epilepsy models. This marked the transition from theoretical interest to translational neuromodulation (Chen & Liu, 2025). The first human implantation occurred in 1988, followed by randomized controlled trials in the 1990s. These demonstrated clinically meaningful seizure reductions in drug-resistant epilepsy (Beekwilder & Beems, 2010). The early 2000s and 2010s saw rapid diversification of VNS applications. Studies revealed neuromodulatory, anti-inflammatory, and neuroplasticity-enhancing effects. This catalyzed exploration of VNS for systemic inflammatory diseases and pain syndromes. It also included post-stroke rehabilitation (Fang et al., 2023). Today, VNS stands as a foundational neuromodulation technology with a rich history marked by iterative scientific discovery, clinical translation, and expanding therapeutic scope—reflecting the evolving understanding of the vagus nerve as a central regulator of neural, autonomic, and immune networks. Mechanisms of Action and Rationale for Neuromodulation Vagus nerve stimulation (VNS) exerts its therapeutic effects by activating a highly interconnected neural–autonomic–immune network. Approximately 80–90% of vagal fibers are afferent, carrying sensory input from peripheral organs to the brain. Stimulation of these fibers initiates a cascade of activity beginning in the nucleus tractus solitarius (NTS). This projection extends to key regulatory centers including the locus coeruleus, raphe nuclei, hypothalamus, amygdala, and cortical regions. This broad anatomical reach provides the biological rationale for VNS as a tool capable of reshaping neural excitability, emotional regulation, autonomic tone, and immune function. A central mechanism involves modulation of monoaminergic neurotransmission, particularly norepinephrine and serotonin. Activation of the locus coeruleus increases cortical norepinephrine release, enhancing arousal, attention, and synaptic plasticity—features directly relevant to epilepsy control, mood regulation, and functional recovery after neurological injury (Goggins et al., 2022; Chen & Liu, 2025). Parallel activation of raphe nuclei elevates serotonergic transmission, further supporting mood stabilization and neuroplastic changes. VNS also influences cortical and subcortical excitability by generating network-level desynchronization, reducing hypersynchronous oscillations implicated in seizure propagation (Abdennadher et al., 2024). At the cellular level, VNS enhances activity-dependent plasticity through pathways that increase expression of plasticity-related genes, such as Arc, and through neuromodulator-driven strengthening of adaptive synaptic connections (Malley et al., 2024). Another major component is the cholinergic anti-inflammatory pathway. This pathway is mediated by activation of vagal efferents that regulate cytokine production and immune-cell signaling. Through α7-nicotinic acetylcholine receptor–dependent mechanisms, VNS reduces levels of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6. This influences disease processes in chronic pain, autoimmune disorders, and systemic inflammatory states. Together, these neurophysiological and immunomodulatory mechanisms support the rationale for VNS as a strategic method of influencing distributed neural circuits. By engaging multiple systems simultaneously, VNS achieves therapeutic effects not through a single pathway but through coordinated modulation of brain, autonomic, and immune networks. Together, these neurophysiological and immunomodulatory mechanisms support the rationale for VNS as a strategic method of influencing distributed neural circuits. By engaging multiple systems simultaneously, VNS achieves therapeutic effects not through a single pathway but through coordinated modulation of brain, autonomic, and immune networks. Indications Vagus nerve stimulation (VNS) is used across a growing range of neurological, psychiatric, autonomic, inflammatory, and pain-related disorders, supported by both clinical trials and real-world evidence. The earliest and most established indication is drug-resistant epilepsy, where invasive cervical VNS significantly reduces seizure frequency and improves seizure severity in patients who are not candidates for resective surgery (Beekwilder & Beems, 2010; Goggins et al., 2022). Long-term follow-up demonstrates sustained improvement over years of therapy, making VNS an essential tool in the management of refractory epilepsy. VNS is also approved for treatment-resistant depression, where neuromodulation of the locus coeruleus and serotonergic pathways contributes to clinically meaningful mood improvement. Its antidepressant effects have been supported by observational cohorts and mechanistic data showing enhanced monoaminergic neurotransmission (Austelle et al., 2024; Chen & Liu, 2025). Non-invasive VNS techniques, including auricular (aVNS) and cervical (tcVNS) approaches, have expanded indications further. The FDA has cleared non-invasive VNS for migraine and cluster headache, where modulation of trigeminovascular and autonomic pathways leads to acute pain relief and reduced attack frequency (Goggins et al., 2022; Hilz, 2022). Growing evidence also supports VNS for post-stroke motor rehabilitation, where pairing VNS with physical therapy enhances motor recovery via plasticity-related mechanisms, including neuromodulator-dependent

Drug-resistant epilepsy: Definition, Mechanisms, and Clinical Spectrum

Drug-resistant epilepsy: Definition, Mechanisms, and Clinical Spectrum Drug resistant epilepsy is defined as the failure of two appropriately chosen and tolerated antiseizure medications to achieve sustained seizure freedom. Large clinical cohorts show that once two medication trials have failed, the chance of achieving seizure freedom with additional drugs falls to below seven percent (Pérez Carbonell et al 2019). Drug-resistant epilepsy is a significant condition that requires thorough understanding and management. The biological mechanisms behind drug resistance involve multiple levels of dysfunction. One important model emphasizes persistent excitability within epileptogenic networks which can become self sustaining and poorly responsive to pharmacological attempts to stabilize them. Clinically, drug resistant epilepsy includes a wide range of syndromes. It occurs in focal epilepsy, multifocal epilepsy, generalized epilepsies including Lennox Gastaut syndrome, and in individuals with seizure recurrence after resective surgery (Giordano et al 2017). Many individuals suffering from drug-resistant epilepsy experience ongoing challenges that require comprehensive care. Because drug resistant epilepsy rarely responds to further medication adjustments early transition to non pharmacological therapies is essential. Vagus nerve stimulation is a major option supported by decades of evidence showing reductions in seizure frequency and modulation of epileptic networks across diverse clinical presentations (Toffa et al 2020). Effective treatment for drug-resistant epilepsy is essential for improving patient outcomes. Why Vagus Nerve Stimulation for Drug-resistant Epilepsy Vagus nerve stimulation is an established treatment for patients with drug resistant epilepsy who are not candidates for resective surgery or who continue to experience seizures despite optimal medical therapy. Randomized controlled trials demonstrated that therapeutic stimulation of the left vagus nerve produces a significantly greater reduction in seizure frequency compared with low intensity control stimulation. Patients should be informed about all therapies available for drug-resistant epilepsy. The biological rationale for vagus nerve stimulation is rooted in the anatomy and physiology of the vagus nerve. Most fibers are afferent and project to the nucleus tractus solitarius, which then activates the locus coeruleus. This pathway increases the release of norepinephrine in widespread cortical and subcortical areas including the hippocampus, the amygdala, and the prefrontal cortex. Clinically vagus nerve stimulation is particularly advantageous for focal epilepsy because many patients have multifocal or non localizable epileptogenic networks or seizure foci located in brain regions where surgery is unsafe. It is also effective in syndromes with diffuse network dysfunction such as Lennox Gastaut syndrome and in individuals with seizure recurrence after resective procedures (Giordano et al 2017). Additional benefits include improvements in mood and quality of life which are frequently impaired in drug resistant epilepsy regardless of seizure frequency (Mertens et al 2022 and Toffa et al 2020). Drug-resistant epilepsy necessitates a multifaceted treatment approach to enhance patient quality of life. For these reasons vagus nerve stimulation remains a central evidence supported neuromodulation strategy for drug resistant epilepsy especially for patients with partial onset seizures. Understanding drug-resistant epilepsy is crucial for both patients and healthcare providers. Vagus Nerve Stimulation Procedure & Targets in Drug-resistant Epilepsy Understanding Challenges in Drug-resistant Epilepsy The clinical procedure for vagus nerve stimulation involves implantation of a programmable pulse generator in the upper chest and a lead that delivers electrical pulses to the left cervical vagus nerve. This procedure is performed under general anesthesia and follows a reproducible surgical approach. The management of drug-resistant epilepsy often includes a team of specialists. The target of stimulation is the cervical segment of the vagus nerve which contains a large proportion of afferent fibers projecting to central autonomic and neuromodulatory structures. The stimulation protocols typically use frequencies between twenty and thirty hertz with pulse widths of about two hundred fifty to five hundred microseconds and on intervals of thirty seconds followed by off periods of several minutes. These parameters can be adjusted based on seizure response side effects and device programming goals. More recent models can also deliver automatic stimulation triggered by physiologic markers such as sudden increases in heart rate which often accompany seizure onset (Toffa et al 2020). For patients with drug-resistant epilepsy, continuous monitoring and adjustments are necessary. The therapeutic target of vagus nerve stimulation is therefore not a discrete anatomical structure but a distributed network involving brainstem nuclei limbic circuits and thalamocortical pathways. By engaging this widespread system vagus nerve stimulation can modulate seizure propagation across multiple cortical and subcortical regions which is particularly valuable in focal and multifocal epilepsy where a single resectable focus is not identifiable. The procedure’s safety profile and its ability to provide sustained neuromodulatory influence make it an essential option in the treatment of drug resistant epilepsy especially for partial onset seizures. Clinical Outcomes & Long-Term Efficacy of VNS in Drug-resistant epilepsy Clinical outcomes for drug-resistant epilepsy patients can vary based on individual responses to treatment. Clinical outcomes of vagus nerve stimulation have been characterized over more than three decades of experience. These consistently demonstrate meaningful seizure reduction in individuals with drug resistant epilepsy. Early randomized controlled trials comparing therapeutic stimulation with low intensity control stimulation showed significant reductions in seizure frequency in the treatment group with responder rates around thirty percent at three months. Long term observational studies reveal that the efficacy of vagus nerve stimulation increases progressively with continued therapy. A notable pattern is the incremental rise in responder rates from the first year onward. Patients with drug-resistant epilepsy can benefit from long-term studies that track their progress. Clinical outcomes extend beyond seizure frequency. Improvements in mood, anxiety, and overall quality of life have been repeatedly documented even when seizure reduction is modest. These effects do not correlate directly with seizure control and appear to arise from stimulation of neuromodulatory circuits including the locus coeruleus and dorsal raphe nuclei which regulate emotional processing and arousal (Mertens et al 2022). Long term efficacy also varies by epilepsy type. Vagus nerve stimulation is effective in focal and multifocal epilepsy and provides benefit in generalized epilepsies with complex network involvement including Lennox Gastaut syndrome. Patients who have undergone unsuccessful resective surgery or those with non localizable or multilobar epileptogenic networks are among the groups most

Cluster Headache, Migraine and Vagus Nerve Stimulation

Cluster Headache and Migraine: Definition, Mechanisms, and Clinical Spectrum Cluster headache is a primary trigeminal autonomic cephalalgia characterized by severe unilateral periocular pain lasting 15 to 180 minutes. It is accompanied by ipsilateral cranial autonomic symptoms such as lacrimation, rhinorrhea, and ptosis (Holle Lee and Gaul, 2016). Both disorders share a common foundation in activation of the trigeminovascular system, which mediates nociceptive signaling and contributes to neuropeptide release and neuroinflammation. Clinically, cluster headache is noted for its extreme pain intensity and circadian rhythmicity. There is frequent misdiagnosis, particularly in women, due to overlapping migraine-like symptoms (Goadsby et al., 2025). Why Vagus Nerve Stimulation for Cluster Headache and Migraine Understanding Headache Types: Cluster and Migraine Vagus nerve stimulation has emerged as a promising neuromodulatory strategy for both cluster headache and migraine because these disorders share pathophysiological mechanisms that are strongly influenced by vagal afferent input. Clinical evidence shows that noninvasive vagus nerve stimulation modulates trigeminal allodynia, reduces glutamatergic activity in the trigeminal nucleus caudalis, and produces antinociceptive effects in both preclinical and human studies (Holle Lee and Gaul, 2016). In cluster headache specifically, the trigeminal–autonomic reflex is a defining mechanism. VNS attenuates parasympathetic overactivation and can modulate cranial autonomic symptoms. Noninvasive approaches also address the limitations of implanted devices by avoiding surgical risks while offering high tolerability and favorable safety profiles. Systematic reviews highlight that transcutaneous VNS yields mainly mild, transient adverse effects without increased risk compared to control conditions (Kim et al., 2022). Together, these mechanistic and clinical data position vagus nerve stimulation as a targeted, safe, and biologically grounded treatment option for patients with migraine and cluster headache whose disease reflects dysfunction across vagally mediated pain and autonomic pathways. Vagus Nerve Stimulation Procedure & Targets in Cluster Headache and Migraine Vagus nerve stimulation for cluster headache and migraine is delivered either invasively through surgically implanted cervical electrodes or noninvasively using transcutaneous stimulation devices designed to activate the cervical or auricular branches of the vagus nerve. In cluster headache, the therapeutic target is the trigeminal–autonomic reflex arc. Stimulation of cervical vagal afferents can counteract parasympathetic overactivation and reduce cranial autonomic symptoms by altering signaling within the sphenopalatine and trigeminovascular pathways (Holle Lee and Gaul, 2016). In migraine, VNS targets broader pain modulation circuits. Functional imaging studies demonstrate that VNS alters connectivity within default mode, vestibular, and limbic networks that are disrupted in migraineurs, particularly regions such as the inferior temporal gyrus, orbitofrontal cortex, and cerebellar lobules involved in pain processing and sensory integration (Rao et al., 2023). The transcutaneous auricular approach stimulates the auricular branch of the vagus nerve at the tragus or concha. Although anatomically distinct from cervical stimulation, this method similarly engages the nucleus tractus solitarius and downstream antinociceptive circuits, while avoiding unintended activation of efferent cardiac fibers (Kim et al., 2022). Clinical Outcomes & Long-Term Efficacy of VNS in Cluster Headache and Migraine Vagus nerve stimulation has demonstrated clinically meaningful benefits for people living with cluster headache and migraine. It offers both rapid relief during attacks and sustained reductions in headache burden over time. In migraine, VNS has demonstrated benefits across several key outcomes: fewer monthly headache days, shorter attacks, and lower overall pain intensity. Auricular stimulation provides further evidence for migraine relief. Studies show reduced attack duration and frequency, accompanied by modulation of brainstem and thalamocortical pathways central to migraine pathophysiology (Rao et al., 2023). Taken together, these findings demonstrate that VNS is not simply an alternative to medication but a clinically validated neuromodulation tool capable of delivering meaningful, durable improvements in both cluster headache and migraine. Side Effects & Safety Profile Vagus nerve stimulation is considered a highly safe and well-tolerated neuromodulation option for both cluster headache and migraine. Across clinical studies, noninvasive VNS consistently shows a side-effect profile that is mild, transient, and comparable to placebo, making it one of the safest therapeutic tools available in headache management. Large-scale safety analyses reinforce these findings. A systematic review evaluating more than six thousand participants undergoing transcutaneous vagus nerve stimulation found no increased risk of serious adverse events, and importantly, no causal relationship between VNS and major cardiac, respiratory, or neurological complications (Kim et al., 2022). For auricular VNS, the safety profile remains similarly favorable. Reported effects such as mild ear discomfort or temporary skin irritation are rare and self-limited, further supporting the method’s feasibility for long-term preventive use (Kim et al., 2022). Overall, the available evidence demonstrates that VNS offers a strong balance of efficacy and safety, enabling patients to pursue meaningful headache relief without the burden of significant side effects. What to Expect During Recovery and Follow-Up Recovery and follow-up after starting vagus nerve stimulation are typically smooth, as the therapy does not require surgery and users can begin applying sessions immediately. For individuals treating cluster headache, relief during acute attacks may appear rapidly, sometimes within minutes. Follow-up visits play an essential role in maintaining long-term efficacy. These appointments typically involve reviewing symptom patterns, fine-tuning stimulation schedules, and ensuring the technique is being applied correctly. Most patients integrate stimulation seamlessly into their daily routines, whether using VNS as a stand-alone tool or alongside medications and behavioral strategies. Predictors of Successful VNS Outcomes Several patient and disease characteristics appear to influence how well individuals respond to vagus nerve stimulation for cluster headache and migraine. Another factor consistently associated with successful outcomes is early symptom responsiveness. Individuals who experience noticeable reductions in pain intensity or attack duration during the first weeks of use tend to maintain long-term benefit. This pattern likely reflects more efficient engagement of the vagus nerve’s afferent pathways and more adaptable central pain networks (Holle Lee & Gaul, 2016). Imaging studies strengthen this concept: patients showing early normalization of functional connectivity in sensory and limbic circuits also report greater improvement in headache burden (Rao et al., 2023). Another factor consistently associated with successful outcomes is early symptom responsiveness. Individuals who experience noticeable reductions in pain intensity or attack duration during the first weeks of use tend to maintain long-term benefit. Consistency of